IC
SEEL

Ikarian Capital’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Ikarian Capital’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-67
Closed -$215K – 212
2022
Q1 		$215K Buy
67
+3
+5% +$12.9K 0.03% 162
2021
Q4 		$398K Hold
64
– – 0.06% 138
2021
Q3 		$589K Sell
64
-9
-12% -$77.3K 0.04% 180
2021
Q2 		$739K Sell
73
-114
-61% -$1.87M 0.06% 172
2021
Q1 		$3.58M Buy
+187
New +$2.18M 0.12% 155

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's SEEL Position: Q2 2022 in Review

Ikarian Capital sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 67 shares — an estimated $215K sold.

Ikarian Capital first reported a position in SEEL in Q1 2021 and held it in 5 quarters. The position peaked at $3.58M in Q1 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Ikarian Capital reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 67 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $215K.
  • Ikarian Capital first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Seelos Therapeutics, Inc. Common Stock position peaked at $3.58M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.